Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

Meet FluoGuide

Annual General Meeting (Company's address): 23 April 2020 at 10.00 AM.

Excellent result of FluoGuide’s FG001 guiding surgical removal of cancer is published

News


January 15, 2020

FluoGuide A/S’s (“FluoGuide”) compound FG001 lights up the cancer and its invasive growth and has demonstrated potential to vastly improve the radicality of surgery in preclinical studies. FluoGuide can announce that data which confirms FG001’s potential in guiding surgical removal of pancreatic cancer has now also been published in peer reviewed journal.

The study aimed at investigating the resection of the human pancreatic cancer using an orthotopic xenograft pancreatic cancer model and also to investigate if fluorescent-guided imaging could locate additional metastases after conventional removal of metastasis under traditional surgical white light. As previously communicated, this preclinical study was conducted similarly to the way human cancer patients are treated.

The result demonstrated that FG001 helped to identify and remove local additional metastases in 50% of the subjects that were overlooked during the standard white light procedure. The study was conducted with the aim of evaluating the potential clinical benefit of FG001 to completely remove local cancer during surgery using human cancer, performed by a surgeon who operates on humans and using standard surgical equipment.

The data underlined the vast potential of uPAR target products in guiding surgical removal of cancer beyond glioblastoma which has the primary focus of FluoGuide. Pancreatic cancer remains one of the deadliest cancers and the 5-year survival rate is very low, making the need for improved treatment extensive.

The article is titled “Improved surgical resection of metastatic pancreatic cancer using uPAR targeted in vivo fluorescent guidance: comparison with traditional white surgery”. FluoGuide’s Chief Scientific Officer Andreas Kjær is one of the co-writers of the research paper (link to article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824874/).

Andreas Kjær, CSO comments:
“We are now producing the FG001 in a quality for use in patients. We have everything in place and the surgeons are ready to begin testing the new technology. That way, they can become even better at what they are doing already – removing cancer and thus hopefully healing patients.”

Additional material:
The link https://youtu.be/6AgQiTsozXQ shows a movie of the removal of the cancer, where cancer is left behind without use of FG001.